Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $51.3 million.

  • Xeris Biopharma Holdings' Other Accumulated Expenses rose 14983.67% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year increase of 14983.67%. This contributed to the annual value of $29.1 million for FY2024, which is 3131.07% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Other Accumulated Expenses stood at $51.3 million, which was up 14983.67% from $33.2 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Other Accumulated Expenses ranged from a high of $51.3 million in Q3 2025 and a low of $6.8 million during Q3 2021
  • For the 5-year period, Xeris Biopharma Holdings' Other Accumulated Expenses averaged around $22.1 million, with its median value being $20.5 million (2024).
  • In the last 5 years, Xeris Biopharma Holdings' Other Accumulated Expenses soared by 18488.65% in 2022 and then plummeted by 480.19% in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Accumulated Expenses (Quarter) stood at $15.0 million in 2021, then rose by 11.81% to $16.8 million in 2022, then soared by 31.7% to $22.1 million in 2023, then skyrocketed by 31.31% to $29.1 million in 2024, then skyrocketed by 76.26% to $51.3 million in 2025.
  • Its Other Accumulated Expenses stands at $51.3 million for Q3 2025, versus $33.2 million for Q2 2025 and $30.7 million for Q1 2025.